Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25039979 | 0.82 | THRB (0.42) | TAAR1ADRA2AADRA2CCYP2D6LMNA | |
| SCHEMBL609266 | 0.82 | THRB (0.42) | TAAR1ADRA2AADRA2CCYP2D6LMNA | |
| SCHEMBL13479273 | 0.80 | ADRA2C (0.41) | TAAR1ADRA2AADRA2CCYP2D6LMNA | |
| SCHEMBL908216 | 0.80 | TAAR1 (0.50) | TAAR1ADRA2AADRA2CCYP2D6LMNA | |
| SCHEMBL10893989 | 0.79 | ADRA2C (0.44) | TAAR1ADRA2AADRA2CCYP2D6LMNA | |
| SCHEMBL19725369 | 0.78 | SLC6A4 (0.43) | TAAR1ADRA2AADRA2CLMNAKDM4E | |
| SCHEMBL608542 | 0.77 | L3MBTL1 (0.41) | TAAR1ADRA2ACYP2D6LMNAALDH1A1 | |
| SCHEMBL8486238 | 0.75 | ADRA2A (0.38) | TAAR1ADRA2AADRA2CCYP2D6LMNA | |
| SCHEMBL17288648 | 0.75 | MIF (0.35) | TAAR1ADRA2AADRA2CCYP2D6LMNA | |
| SCHEMBL19519886 | 0.75 | TAAR1 (0.48) | TAAR1ADRA2AADRA2CCYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2072083-B1 | Utilisation of 2.4'-dimethyl-propiophenon as an aroma | SYMRISE AG (DE) | 2012-02-15 | — | — | EP | claimed |
| EP-2072083-A1 | Utilisation of 2.4'-dimethyl-propiophenon as an aroma | Symrise GmbH & Co. KG (DE) | 2009-06-24 | — | — | EP | claimed |
| EP-1682230-A1 | 4,8-DIMETHYL-7-NONEN-2-ONE AND 4,8-DIMETHYLNONAN-2-ONE USED AS PERFUMES | Symrise GmbH & Co. KG (DE) | 2006-07-26 | — | — | EP | claimed |
| WO-2005004825-A1 | 4,8-DIMETHYL-7-NONEN-2-ONE AND 4,8-DIMETHYLNONAN-2-ONE USED AS PERFUMES | SYMRISE GMBH & CO. KG (DE) | 2005-01-20 | — | — | WO | claimed |
| EP-2072083-B1 | Utilisation of 2.4'-dimethyl-propiophenon as an aroma | SYMRISE AG (DE) | 2012-02-15 | — | — | EP | disclosed |
| US-20090162308-A1 | USE OF 2,4'-DIMETHYLPROPIOPHENONE AS A FRAGRANCE SUBSTANCE | SYMRISE GMBH & CO. KG (DE) | 2009-06-25 | — | — | US | disclosed |
| EP-2072083-A1 | Utilisation of 2.4'-dimethyl-propiophenon as an aroma | Symrise GmbH & Co. KG (DE) | 2009-06-24 | — | — | EP | disclosed |
| EP-1682230-A1 | 4,8-DIMETHYL-7-NONEN-2-ONE AND 4,8-DIMETHYLNONAN-2-ONE USED AS PERFUMES | Symrise GmbH & Co. KG (DE) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005004825-A1 | 4,8-DIMETHYL-7-NONEN-2-ONE AND 4,8-DIMETHYLNONAN-2-ONE USED AS PERFUMES | SYMRISE GMBH & CO. KG (DE) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090162308-A1 | USE OF 2,4'-DIMETHYLPROPIOPHENONE AS A FRAGRANCE SUBSTANCE | CYP1B1, CYP4A22, ROS1 | TAAR1 2219/4885ADRA2A 830/4885ADRA2C 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.